Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.
This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.
The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.
Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.
Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.
There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.
Industry News
- Machine Learning Advances in Parkinson’s Disease Researchby Bioengineer on July 2, 2025 at 2:14 am
In the rapidly evolving landscape of medical technology, the diagnosis of Parkinson’s disease (PD) stands poised for a transformative leap through the integration of machine learning (ML) methodologies. Parkinson’s disease, a neurodegenerative disorder characterized by complex motor and non-motor symptoms, presents an enduring challenge for early and accurate diagnosis due to its heterogeneous nature. Recent
- Computational Study Reveals Amygdalin’s Potent Binding and Stabilizing Effects on HER2 Receptor for Breast Cancer Therapyby Bioengineer on July 2, 2025 at 2:13 am
image: Article Graphical Abstract view more Credit: Lucas P. Kwiyukwa, Geradius Deogratias, Fidele Ntie-Kang, Lucas Paul. This study investigates the potential of amygdalin, a natural compound found in almonds, peaches, and apples, as a therapeutic agent for HER2-positive breast cancer. HER2 (human epidermal growth factor receptor 2) is overexpressed in a significant percentage of aggressive breast
- Interpretable Model Predicts Early Liver Metastasisby Bioengineer on July 2, 2025 at 1:55 am
In a groundbreaking advancement bridging oncology and artificial intelligence, researchers have unveiled a cutting-edge machine learning model capable of predicting early liver metastasis in patients undergoing surgery for pancreatic ductal adenocarcinoma (PDAC). This development offers a beacon of hope in the battle against one of the most aggressive and lethal cancer types, where metastasis significantly
- Nerve-Specific Fluorescence Enhances Head, Neck Surgeryby Bioengineer on July 2, 2025 at 1:44 am
In a groundbreaking development poised to transform the landscape of surgical oncology, a team of researchers has unveiled the first clinical trial demonstrating the use of nerve-specific fluorescence during head and neck surgeries. The Phase 1 trial, recently published in Nature Communications, showcases the remarkable precision and potential safety benefits of this innovative imaging technique
- m6A Modification of MEF2A Reduces Cetuximab Responseby Bioengineer on July 2, 2025 at 1:38 am
In a groundbreaking study poised to reshape the landscape of colorectal cancer therapeutics, researchers have unveiled a novel molecular mechanism by which N6-methyladenosine (m6A) modification on the transcription factor MEF2A significantly undermines the effectiveness of cetuximab treatment. This discovery, recently published in Cell Death Discovery, elucidates how the intricate epitranscriptomic alterations driven by m6A modifications
- Adapting Vulnerable Communities to Urban Heat Challengesby Bioengineer on July 2, 2025 at 1:16 am
In the escalating battle against climate change, urban environments face a particularly fierce adversary: the intensifying urban heat island (UHI) effect. As cities expand and densify, they inadvertently create localized hotspots where temperatures soar well above surrounding rural areas. This phenomenon presents a significant challenge to global sustainability efforts, particularly those encapsulated in the United
- Time-to-Event Analysis Enhances Parkinson’s Trial Accuracyby Bioengineer on July 2, 2025 at 1:14 am
In the evolving landscape of Parkinson’s disease research, assessing the true efficacy of potential therapeutics has been an enduring challenge. A groundbreaking study published in npj Parkinson’s Disease by Pagano, Trundell, Simuni, and colleagues introduces a powerful statistical approach that promises to refine our understanding of therapeutic benefits by mitigating the confounding effects of symptomatic
- New Study Connects Blood Metabolites and Immune Cells to Elevated Urolithiasis Riskby Bioengineer on July 2, 2025 at 1:07 am
A groundbreaking study recently published in the prestigious journal Genes & Diseases unveils novel insights into the complex interplay between immune cell characteristics, blood metabolites, and the risk of developing urolithiasis, a condition marked by the formation of urinary stones. Utilizing advanced methods such as Mendelian randomization (MR) and mediation analysis, the research pioneers a
- Illinois Researchers Showcase Breakthrough in Giant Photonic Isolation and Gyrationby Bioengineer on July 2, 2025 at 1:04 am
Researchers at the Illinois Grainger College of Engineering have made a groundbreaking advancement in the field of integrated photonics, introducing a novel approach to achieving asymmetric couplings using modulation techniques. This innovative work not only sheds light on the complexities of topological physics but also introduces potential applications in optical non-reciprocity and photonic gyration. The
- Sleep, Fatigue, Depression Impact Breast Cancer Qualityby Bioengineer on July 2, 2025 at 12:55 am
In a groundbreaking new study conducted at an oncology hospital in Cairo, Egypt, researchers have unveiled critical insights into the intricate interplay between sleep disturbance, cancer-related fatigue, and depression, demonstrating their collective and individual impacts on the quality of life (QoL) of breast cancer patients undergoing chemotherapy. This investigation, set between November 2024 and February
- Ethnic Disparities in UK COVID-19 and Heart Diseaseby Bioengineer on July 2, 2025 at 12:25 am
In a comprehensive and groundbreaking study recently published in Nature Communications, researchers have shed light on the complex interplay between ethnicity, COVID-19 mortality, and cardiovascular disease (CVD) in the populations of England and Wales from 2020 to 2022. This extensive investigation reveals deeply rooted health disparities manifesting along ethnic lines, emphasizing how socio-demographic variables continue
- Revolutionary Software Tool Aims to Enhance Understanding of Childhood Cancerby Bioengineer on July 1, 2025 at 11:57 pm
A groundbreaking software innovation originating from Melbourne has gained attention for its potential to transform our understanding of cardiac tumors in children. The new technology, named VR-Omics, represents a significant advancement in the field of pediatric oncology, specifically focusing on cardiac rhabdomyoma, the most prevalent type of heart tumor found in children. Researchers from the
- Eco-Friendly Farming Enhances Biodiversity and Crop Yields, Calls for Updated Subsidiesby Bioengineer on July 1, 2025 at 11:56 pm
A groundbreaking four-year investigation into agroecological farming has revealed that nature-friendly agricultural practices boost both biodiversity and crop yields, yet may require governmental subsidies to be economically viable compared to conventional intensive farming. Spearheaded by the UK Centre for Ecology & Hydrology (UKCEH) in collaboration with Rothamsted Research, this extensive study represents the first comprehensive
- How Motor Symmetry Affects Parkinson’s Non-Motor Symptomsby Bioengineer on July 1, 2025 at 11:55 pm
In the landscape of neurodegenerative diseases, Parkinson’s disease (PD) stands as a formidable challenge to both clinicians and patients, with its multifaceted manifestations extending far beyond the well-characterized motor symptoms. A recent systematic review by Voruz, Guérin, and Péron, published in the renowned journal npj Parkinson’s Disease, casts new light on the intricate relationship between
- Women Aged 65 and Older Remain at Increased Risk for HPV-Related Cervical Cancerby Bioengineer on July 1, 2025 at 11:54 pm
Emerging research from a comprehensive observational study published in Gynecology and Obstetrics Clinical Medicine has shed new light on the ongoing risks of cervical cancer among women aged 65 and older, emphasizing the urgent need for renewed screening initiatives in this demographic. Despite prevailing medical guidelines advising the cessation of cervical cancer screening past the
- Plants Prefer Friendly Environments Over Adaptation, Study Findsby Bioengineer on July 1, 2025 at 11:46 pm
As the earth’s climate continues to shift, understanding how species adapt—or fail to adapt—to changing environmental conditions remains a cornerstone question in evolutionary biology. A groundbreaking study from researchers at the University of California, Davis, has brought new insights into this complex dynamic by examining a wildflower clade known as jewelflowers (Streptanthus). This research, published
- AI Model Predicts 5-Year Liver Cancer Survivalby Bioengineer on July 1, 2025 at 11:42 pm
In a pioneering advance intersecting oncology and artificial intelligence, researchers have unveiled a machine learning model capable of accurately forecasting five-year overall survival in patients with hepatocellular carcinoma (HCC). This breakthrough arrives at a critical juncture for liver cancer prognosis, where traditional methods have struggled to balance precision with the practical constraints of limited clinical
- Global Seafood Trade: Nutrients and Nutritional Affordabilityby Bioengineer on July 1, 2025 at 11:27 pm
In the evolving landscape of global food security, the intricate web of seafood trade emerges as a pivotal factor shaping nutritional outcomes across nations. A recent study published in Nature Communications by Liu, Y., Smith, M.D., Abbott, J.K., and their colleagues offers a comprehensive analysis of the global seafood trade, investigating how the transfer of
- Using Serology to Identify Trachoma Eliminationby Bioengineer on July 1, 2025 at 11:19 pm
In the global fight against neglected tropical diseases, trachoma—a contagious bacterial infection of the eye—has persisted as a significant cause of preventable blindness, predominantly affecting the poorest regions of the world. Recent advances in epidemiological monitoring and immunological assays are now illuminating new avenues for the definitive classification of trachoma elimination. A groundbreaking study by
- RCOR1 Drives Myoblast Differentiation and Muscle Repairby Bioengineer on July 1, 2025 at 11:13 pm
In a groundbreaking study published in Cell Death Discovery, researchers have unveiled the pivotal role of RCOR1 (REST corepressor 1) in driving myoblast differentiation and facilitating muscle regeneration. This discovery represents a significant leap forward in understanding the molecular mechanisms governing muscle repair and offers promising avenues for therapies targeting muscular dystrophies and age-related muscular
- Catalio's $400M fund takes advantage of 'historic buyer's market in biotech'on July 1, 2025 at 3:51 pm
Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch two new companies.
- Is an HIV cure possible? The future of HIV therapyby Jules Adam on July 1, 2025 at 1:30 pm
Delve into the field of HIV treatment development. Since the virus was discovered, treatments have improved, but are we close to a cure? The post Is an HIV cure possible? The future of HIV therapy appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reachon July 1, 2025 at 11:14 am
After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset PCS3117 is too far away.
- Concentra acquires IGM Biosciences, continuing M&A streak with struggling biotechson July 1, 2025 at 9:59 am
Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences for $1.25 per share.
- ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operationson July 1, 2025 at 9:12 am
Oncternal Therapeutics’ ROR1 programs have gone out with a whimper, offloaded to Ho’ola Therapeutics for $3 million upfront as the biotech winds down its operations.
- Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering Atai mergeron July 1, 2025 at 8:06 am
Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the biotech’s merger with mental health-focused atai Life Sciences.
- Sanofi takes up option on Adagene biospecific and invests $25M, shielding partner from runway riskon July 1, 2025 at 7:54 am
Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a third program and agreeing to sponsor a trial of its partner’s lead candidate.
- BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinventon July 1, 2025 at 4:57 am
BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.
- Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blockeron July 1, 2025 at 3:53 am
Fosun Pharma subsidiary Henlius Biotech is paying $10 million upfront for regional rights to HanchorBio’s phase 2 CD47 blocker.
- 'Emergency' at Apple Tree: VC sues key investor, warns portfolio biotechs are on brink of collapseon June 30, 2025 at 2:53 pm
Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the investor has failed to meet its monetary commitments and warning of immediate consequences for its biotech portfolio.
- Life sciences in Wales: biotechs in the scene in 2025by Roohi Mariam Peter on June 30, 2025 at 1:00 pm
As biotech startups navigate the growing biotech sector in Wales, here are five biotech companies that are making waves in 2025. The post Life sciences in Wales: biotechs in the scene in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3on June 30, 2025 at 10:15 am
Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according to the pharma.
- AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T marketon June 30, 2025 at 9:29 am
AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline.
- Pfizer expands AI-powered small-molecule discovery collab with XtalPion June 30, 2025 at 9:27 am
Pfizer has added another chapter to its long-running drug discovery collaboration with Chinese tech startup XtalPi, this time upgrading their molecular modeling work.
- INmune flunks phase 2 Alzheimer's trial, focuses on subgroup efficacy to fuel partnering planson June 30, 2025 at 8:35 am
A phase 2 study of INmune Bio’s TNF inhibitor in Alzheimer’s disease has missed its primary endpoint, wiping 60% off the biotech share price.
- Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDAon June 30, 2025 at 7:48 am
The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor candidate.
- Pliant ends lung disease program after assessing rise in adverse events from bexotegrast trialon June 30, 2025 at 4:50 am
Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of adverse events from a 2b/3 trial of its lead candidate bexotegrast.
- Psychedelics sans side effects: neuroplastogens gain groundby Roohi Mariam Peter on June 27, 2025 at 1:00 pm
The past year has seen several developments in the neuroplastogens field, including Elkedonia’s seed funding to address neuropsychiatric disorders. The post Psychedelics sans side effects: neuroplastogens gain ground appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacleon June 27, 2025 at 11:17 am
Investors sued CytoDyn and former executives for allegedly misleading shareholders on the status of its potential treatment for HIV and COVID-19.
- Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyouton June 27, 2025 at 8:38 am
Turnstone Biologics has limped to the exit. Xoma Royalty is buying Turnstone for less than $8 million, marking a low-profile end for a company that pulled in hundreds of millions of dollars from investors and partners.
- Humacyte: Saving lives with lab-grown blood vessels in conflict zonesby Jules Adam on June 27, 2025 at 8:00 am
This week we spoke to Humacyte founder, Laura Niklason about the real-world applications for lab-grown blood vessels in conflict zones. The post Humacyte: Saving lives with lab-grown blood vessels in conflict zones appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Argenx signs $1.5B pact to turn Unnatural Products' macrocyclic peptides to 'undruggable' targetson June 27, 2025 at 5:42 am
Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian biotech Unnatural Products to hunt down “undruggable” targets.
- Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trialson June 27, 2025 at 4:11 am
Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.
- Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asseton June 26, 2025 at 4:15 pm
Alphabet’s Calico Life Sciences is inking a deal worth up to $571 million biobucks for the rights to investigational IL-11 directed therapeutics from Mabwell Bioscience, including a clinical-stage monoclonal antibody for age-related diseases.
- Chutes & Ladders—Incyte taps new CEO after longtime leader hangs up his hatby , on June 26, 2025 at 3:00 pm
Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar commercial drugmaker it is today. Taking his place at the helm is Bill Meury, effective immediately.
- How can treatment strategies evolve to address the challenges in chronic lymphocytic leukemia?by External Contributor on June 26, 2025 at 1:00 pm
Learn how insights and continuous therapy are transforming chronic lymphocytic leukemia care, empowering patients to live beyond uncertainty. The post How can treatment strategies evolve to address the challenges in chronic lymphocytic leukemia? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Invivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccineson June 26, 2025 at 10:14 am
Invivyd has touted its follow-up to the FDA-authorized monoclonal antibody Pemgarda as potentially offering better protection against COVID-19 than available vaccines.
- Puerto Rico: The Bioscience Reshoring Powerhouse the Industry Can’t Afford to Misson June 25, 2025 at 2:25 pm
With decades of excellence in biosciences, Invest PR’s CEO shares how the island is uniquely positioned to lead the reshoring movement.
- ALS: how close are we to a cure?by Roohi Mariam Peter on June 25, 2025 at 1:00 pm
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years. The post ALS: how close are we to a cure? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystemby Willow Shah-Neville on June 24, 2025 at 1:00 pm
Discover what makes Paris's biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters in Europe. The post Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Turning plastic into medicine: Closing the loop on pharma productionby Jules Adam on June 23, 2025 at 3:00 pm
Find out about the University of Edinburgh's work to convert our common plastic wast into the wildly used paracetamol. The post Turning plastic into medicine: Closing the loop on pharma production appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- SAP, Answerthink Help Emerging Biopharma Firms Scale With Confidenceon June 20, 2025 at 1:02 pm
Leaders discuss how built-in best practices and automation streamline growth for lean life sciences teams
- Stem cell therapy: a potential cure for hearing loss?by Roohi Mariam Peter on June 20, 2025 at 1:00 pm
As stem cell research gains momentum, researchers are looking at ways to use the therapy to treat hearing loss. The post Stem cell therapy: a potential cure for hearing loss? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Special Episode: The 2025 BIO International Conventionby Dylan Kissane on June 20, 2025 at 8:00 am
In this week’s episode we meet three innovators on the floor in Boston and find out what their BIO experience has been like The post Special Episode: The 2025 BIO International Convention appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- 10 cultured meat companies driving sustainable food in 2025by Willow Shah-Neville on June 18, 2025 at 1:00 pm
Learn more about 10 of the top cultured meat companies in biotech looking to pave the way for a sustainable future. The post 10 cultured meat companies driving sustainable food in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- From undruggable to oral therapy: The rise of STAT6 degradersby Jules Adam on June 18, 2025 at 8:00 am
Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment. The post From undruggable to oral therapy: The rise of STAT6 degraders appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Protecting Your Drug Patent in Global Markets: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 27, 2025 at 9:19 am
Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source
- Drafting Drug Patent Applications for Biologic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 11:45 am
The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source
- Successfully Patenting Drug Combinations: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 9:57 am
Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source
- Effective Strategies for Generic Drug Price Settingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 25, 2025 at 9:17 am
The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source
- Optimizing the Generic Drug Supply Chain: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 11:56 pm
Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source
- FDA Updates: What Do the Latest Changes Mean for Generic Drug Approval?by Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 8:55 pm
Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source
- Regulatory Challenges in the Latin American Generic Drug Marketby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 4:10 pm
Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source
- Analyzing the cost-effectiveness of biosimilars in different healthcare systemsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 23, 2025 at 11:27 am
The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source
- How to Achieve High-Quality Standards in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 20, 2025 at 11:21 am
Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source
- The Role of Quality Assurance in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 19, 2025 at 11:07 am
The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source
- DrugChatter: Can lurbinectedin treat ovarian cancer?by DrugChatter on February 19, 2025 at 6:44 am
Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source
- Regulatory considerations for biosimilar clinical efficacy trialsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 3:27 pm
Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source
- The basics of drug patent searchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 10:38 am
Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source
- Navigating the Generic Drug Approval Process: A Comprehensive Guideby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 17, 2025 at 10:33 am
Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source
- Strategies for successful biosimilar-to-biosimilar switchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 16, 2025 at 4:04 pm
The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source
- Study Reveals Key Predictors of Early Patent Challenges for FDA-Approved Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 14, 2025 at 11:40 am
The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source
- The Role of Partnerships in Generic Drug Developmentby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 13, 2025 at 9:12 am
Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source
- DrugChatter: Does fish oil interact with vascepa?by DrugChatter on February 12, 2025 at 9:10 pm
Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source
- How to Manage Generic Drug Development Timelines: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 12, 2025 at 9:10 am
The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source
- DrugChatter: How does lipitor affect white wine?by DrugChatter on February 11, 2025 at 4:56 pm
The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source
- Fierce Biotech Layoff Tracker 2025: BMS cuts 68 more roles in NJ; Sage to lay off all staffby , on December 23, 2024 at 11:52 am
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
- Announcing DIYbiosphere: an open source project to connect DIYbio related activities worldwideby Jason Bobe on March 17, 2018 at 10:53 am
With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...
- DIYbio events for the week of September 3by scstowell on September 3, 2017 at 8:29 pm
Here are your events for the week Sunday, September 3 Oakland, CA, USA – Open Insulin Lab Day Work on...
- DIYbio events for the remainder of the week of August 27by scstowell on August 28, 2017 at 4:30 am
Here are your events for the remainder of the week Monday, August 28 Oakland, CA, USA – Plant Bio Group...
- DIYbio events for the week of August 20by scstowell on August 18, 2017 at 4:34 am
Here are your DIYbio events for the week Sunday, August 20 Cincinnati, OH, USA – Science Book Club – The...
- DIYbio events for remainder of the week of August 13by scstowell on August 14, 2017 at 1:22 am
Here are your DIYbio events for the remainder of the week Monday, August 14 Brooklyn, NY, USA – Biotextiles: Grow...
- DIYbio Events for the week of August 6by scstowell on August 1, 2017 at 4:49 pm
Here are your events for the week. Sunday, August 6 Brooklyn, NY, USA – Biotech Crash Course Introductory intense hands-on...
- DIYbio events for the week of July 30by scstowell on July 28, 2017 at 3:29 am
Here are your DIYbio events for the week of July 30 Sunday, July 30 Brooklyn, NY, USA – Summer Ferments ...
- DIYbio events for remainder of the week of January 8by scstowell on January 8, 2017 at 9:01 pm
Here are your DIYbio events for remainder of the week Monday, January 9 Brooklyn, NY, USA Open Night: PCR &...
- DIYbio events for the week of October 16by scstowell on October 13, 2016 at 3:43 pm
Here are your DIYbio events for the week On Sunday Durham has Edward Richards giving a talk “Current Issues In...
- DIYbio events for the week of October 9by scstowell on October 9, 2016 at 5:40 pm
Here are your DIYbio events for the week. On Sunday, Brooklyn begins its Biotechnology Crash Course, Cambridge has a series...